Antiplatelet Drugs: Mechanisms and Risks of Bleeding Following Cardiac Operations

ABSTRACT

Preoperative antiplatelet drug use is common in patients undergoing coronary artery bypass grafting (CABG). The impact of these drugs on bleeding and blood transfusion varies. We hypothesize that review of available evidence regarding drug-related bleeding risk, underlying mechanisms of platelet dysfunction, and variations in patient response to antiplatelet drugs will aid surgeons as they assess preoperative risk and attempt to limit perioperative bleeding. The purpose of this review is to (1) examine the role that antiplatelet drugs play in excessive postoperative blood transfusion, (2) identify possible mechanisms to explain patient response to antiplatelet drugs, and (3) formulate a strategy to limit excessive blood product usage in these patients. We reviewed available published evidence regarding bleeding risk in patients taking preoperative antiplatelet drugs. In addition, we summarized our previous research into mechanisms of antiplatelet drug-related platelet dysfunction. Aspirin users have a slight but significant increase in blood product usage after CABG (0.5 U of nonautologous blood per treated patient). Platelet adenosine diphosphate (ADP) receptor inhibitors are more potent antiplatelet drugs than aspirin but have a half-life similar to aspirin, around 5 to 10 days. The American Heart Association/American College of Cardiology and the Society of Thoracic Surgeons guidelines recommend discontinuation, if possible, of ADP inhibitors 5 to 7 days before operation because of excessive bleeding risk, whereas aspirin should be continued during the entire perioperative period in most patients. Individual variability in response to aspirin and other antiplatelet drugs is common with both hyper- and hyporesponsiveness seen in 5 to 25% of patients. Use of preoperative antiplatelet drugs is a risk factor for increased perioperative bleeding and blood transfusion. Point-of-care tests can identify patients at high risk for perioperative bleeding and blood transfusion, although these tests have limitations. Available evidence suggests that multiple blood conservation techniques benefit high-risk patients taking antiplatelet drugs before operation. Guidelines for patients who take aspirin and/or thienopyridines before cardiac procedures include some or all of the following: (1) preoperative identification of high-risk patients using point-of-care testing; (2) withdrawal of aspirin or other antiplatelet drugs for a few days and delay of operation in patients at high risk for bleeding if clinical circumstances permit; (3) selective perioperative use of evidence-based blood conservation interventions (e.g., short-course erythropoietin, off-pump procedures, and use of intraoperative blood conservation techniques), especially in high-risk patients; and (4) platelet transfusions if clinical bleeding occurs.

Aspirin - aspirin resistance - platelet glycoprotein receptors - postoperative bleeding - clopidogrel - thienopyridines - cardiac surgery - cardiopulmonary bypass

REFERENCES

• 1 Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.  N Engl J Med. 1996;  334 1685-1690
• 2 AuBuchon J P, Birkmeyer J D, Busch M P. Safety of the blood supply in the United States: opportunities and controversies.  Ann Intern Med. 1997;  127 904-909
• 3 Yomtovian R, Lazarus H M, Goodnough L T, Hirschler N V, Morrissey A M, Jacobs M R. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets.  Transfusion. 1993;  33 902-909
• 4 Goodnough L T, Shander A, Brecher M E. Transfusion medicine: looking to the future.  Lancet. 2003;  361 161-169
• 5 Pollock R, Ames F, Rubio P et al.. Protracted severe immune dysregulation induced by cardiopulmonary bypass: a predisposing etiologic factor in blood transfusion-related AIDS?.  J Clin Lab Immunol. 1987;  22 1-5
• 6 Murphy P J, Connery C, Hicks Jr G L, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations.  J Thorac Cardiovasc Surg. 1992;  104 1092-1099
• 7 Goodnough L T. Blood conservation and blood transfusion practices: flip sides of the same coin.  Ann Thorac Surg. 1993;  56 3-4
• 8 Singh A, Doris J, Ferraris V A, Ferraris S P. The cost of excessive postoperative blood transfusion after cardiac operations.  Surg Forum. 1996;  47 652-654
• 9 Trowbridge C C, Stammers A H, Wood G C et al.. Improved outcomes during cardiac surgery: a multifactorial enhancement of cardiopulmonary bypass techniques.  J Extra Corpor Technol. 2005;  37 165-172
• 10 Farrar D, Robertson M S, Hogan C J et al.. Blood usage in an Australian intensive care unit: have we met best practice goals?.  Anaesth Intensive Care. 2004;  32 775-780
• 11 Spiess B D. Transfusion of blood products affects outcome in cardiac surgery.  Semin Cardiothorac Vasc Anesth. 2004;  8 267-281
• 12 Graves E J. National hospital discharge survey: annual summary, 1991.  Vital Health Stat 13. 1993;  114 1-62
• 13 Helm R, Krieger K H. Development and application of a multimodality blood conservation program. In:, Krieger K H, Isom O W, eds. Blood Conservation in Cardiac Surgery. New York: Springer; 1998: 631-670
• 14 Despotis G J, Grishaber J E, Goodnough L T. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery.  Transfusion. 1994;  34 290-296
• 15 Shore-Lesserson L, Manspeizer H E, DePerio M, Francis S, Vela-Cantos F, Ergin M A. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery.  Anesth Analg. 1999;  88 312-319
• 16 Goodnough L T, Despotis G J. Establishing practice guidelines for surgical blood management.  Am J Surg. 1995;  170 (6A Suppl) 16S-20S
• 17 Goodnough L T, Johnston M F, Ramsey G Transfusion Practices Committee of the American Association of Blood Banks et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting.  Ann Thorac Surg. 1990;  50 675-683
• 18 Cannon M A, Beattie C, Speroff T, France D, Mistak B, Drinkwater D. The economic benefit of organizational restructuring of the cardiothoracic intensive care unit.  J Cardiothorac Vasc Anesth. 2003;  17 565-570
• 19 Tyson G S, Sladen R N, Spainhour V, Savitt M A, Ferguson Jr T B, Wolfe W G. Blood conservation in cardiac surgery. Preliminary results with an institutional commitment.  Ann Surg. 1989;  209 736-742
• 20 Ferraris V A, Brown J R, Despotis G J et al.. 2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines.  Ann Thorac Surg. 2011;  In press
• 21 LoCicero III J, Massad M, Gandy K et al.. Aggressive blood conservation in coronary artery surgery: impact on patient care.  J Cardiovasc Surg (Torino). 1990;  31 559-563
• 22 Jones J W, Rawitscher R E, McLean T R, Beall Jr A C, Thornby J I. Benefit from combining blood conservation measures in cardiac operations.  Ann Thorac Surg. 1991;  51 541-544 discussion 545-546
• 23 Boldt J, Knothe C, Welters I, Dapper F L, Hempelmann G. Normothermic versus hypothermic cardiopulmonary bypass: do changes in coagulation differ?.  Ann Thorac Surg. 1996;  62 130-135
• 24 Woodman R C, Harker L A. Bleeding complications associated with cardiopulmonary bypass.  Blood. 1990;  76 1680-1697
• 25 Greilich P E, Carr Jr M E, Carr S L, Chang A S. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage.  Anesth Analg. 1995;  80 459-465
• 26 Holloway D S, Summaria L, Sandesara J, Vagher J P, Alexander J C, Caprini J A. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients.  Thromb Haemost. 1988;  59 62-67
• 27 Ferraris V A, Rodriguez E, Ferraris S P et al.. Platelet aggregation abnormalities after cardiopulmonary bypass.  Blood. 1994;  83 299-301
• 28 Irani M S, Izzat N N, Jones J W. Platelet function, coagulation tests, and cardiopulmonary bypass: lack of correlation between pre-operative and intra-operative whole blood lumiaggregometry and peri-operative blood loss in patients receiving autologous platelet-rich plasma.  Blood Coagul Fibrinolysis. 1995;  6 428-432
• 29 Jung G, Razafindranaibe F, Elkouby A, Durasnel P, Panes F, Monassier J P. Modifications of platelet shape change and ATP release during cardiopulmonary bypass.  Haemostasis. 1995;  25 149-157
• 30 Harker L A, Malpass T W, Branson H E, Hessel II E A, Slichter S J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release.  Blood. 1980;  56 824-834
• 31 Ferraris V A, Ferraris S P, Singh A et al.. The platelet thrombin receptor and postoperative bleeding.  Ann Thorac Surg. 1998;  65 352-358
• 32 Kestin A S, Valeri C R, Khuri S F et al.. The platelet function defect of cardiopulmonary bypass.  Blood. 1993;  82 107-117
• 33 Ferraris V A, Ferraris S P, Moliterno D J Society of Thoracic Surgeons et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary).  Ann Thorac Surg. 2005;  79 1454-1461
• 34 Sethi G K, Copeland J G, Goldman S, Moritz T, Zadina K, Henderson W G. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy . Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting.  J Am Coll Cardiol. 1990;  15 15-20
• 35 Goldman S, Copeland J, Moritz T et al.. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.  Circulation. 1988;  77 1324-1332
• 36 Kallis P, Tooze J A, Talbot S, Cowans D, Bevan D H, Treasure T. Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss—a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina.  Eur J Cardiothorac Surg. 1994;  8 404-409
• 37 Ferraris V A, Ferraris S P, Lough F C, Berry W R. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting.  Ann Thorac Surg. 1988;  45 71-74
• 38 Taggart D P, Siddiqui A, Wheatley D J. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements.  Ann Thorac Surg. 1990;  50 424-428
• 39 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 40 Gurbel P A, O'Connor C M, Cummings C C, Serebruany V L. Clopidogrel: the future choice for preventing platelet activation during coronary stenting?.  Pharmacol Res. 1999;  40 107-111
• 41 Bhatt D L, Chew D P, Hirsch A T, Ringleb P A, Hacke W, Topol E J. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.  Circulation. 2001;  103 363-368
• 42 Lubbe D F, Berger P B. The thienopyridines.  J Interv Cardiol. 2002;  15 85-93
• 43 Sabatine M S, Cannon C P, Gibson C M CLARITY-TIMI 28 Investigators et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.  N Engl J Med. 2005;  352 1179-1189
• 44 Steinhubl S R, Berger P B, Mann III J T CREDO Investigators. Clopidogrel for the Reduction of Events During Observation et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.  JAMA. 2002;  288 2411-2420
• 45 Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
• 46 Ferraris V A, Ferraris S P, Saha S P Society of Thoracic Surgeons Blood Conservation Guideline Task Force et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.  Ann Thorac Surg. 2007;  83 (5 Suppl) S27-S86
• 47 Mahla E, Metzler H, Tantry U S, Gurbel P A. Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.  Ann Thorac Surg. 2010;  90 1040-1051
• 48 Braunwald E, Antman E M, Beasley J W American College of Cardiology et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).  J Am Coll Cardiol. 2002;  40 1366-1374
• 49 Biancari F, Airaksinen K E, Lip G Y. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.  J Thorac Cardiovasc Surg. 2011;  In press
• 50 Harder S, Klinkhardt U, Alvarez J M. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.  Clin Pharmacokinet. 2004;  43 963-981
• 51 Dyke C, Bhatia D. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.  J Cardiovasc Surg (Torino). 1999;  40 505-516
• 52 Pang J T, Fort S, Della Siega A, Cohen E A. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.  J Card Surg. 2002;  17 425-431
• 53 Lee L Y, DeBois W, Krieger K H et al.. The effects of platelet inhibitors on blood use in cardiac surgery.  Perfusion. 2002;  17 33-37
• 54 Silvestry S C, Smith P K. Current status of cardiac surgery in the abciximab-treated patient.  Ann Thorac Surg. 2000;  70 (2 Suppl) S12-S19
• 55 Dyke C M, Bhatia D, Lorenz T J et al.. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.  Ann Thorac Surg. 2000;  70 866-871 discussion 871-872
• 56 Lemmer Jr J H. Clinical experience in coronary bypass surgery for abciximab-treated patients.  Ann Thorac Surg. 2000;  70 (2 Suppl) S33-S37
• 57 Marso S P, Bhatt D L, Roe M T PURSUIT Investigators et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting.  Circulation. 2000;  102 2952-2958
• 58 Bizzarri F, Scolletta S, Tucci E et al.. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.  J Thorac Cardiovasc Surg. 2001;  122 1181-1185
• 59 Ferraris V A, Ferraris S P, Joseph O, Wehner P, Mentzer Jr R M. Aspirin and postoperative bleeding after coronary artery bypass grafting.  Ann Surg. 2002;  235 820-827
• 60 Arora R C, Légaré J F, Buth K J, Sullivan J A, Hirsch G M. Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies.  Ann Thorac Surg. 2004;  78 1547-1554
• 61 Fiore L D, Brophy M T, Lopez A, Janson P, Deykin D. The bleeding time response to aspirin. Identifying the hyperresponder.  Am J Clin Pathol. 1990;  94 292-296
• 62 Ferraris V A, Gildengorin V. Predictors of excessive blood use after coronary artery bypass grafting. A multivariate analysis.  J Thorac Cardiovasc Surg. 1989;  98 492-497
• 63 Quinn M J, Topol E J. Common variations in platelet glycoproteins: pharmacogenomic implications.  Pharmacogenomics. 2001;  2 341-352
• 64 Jefferson B K, Foster J H, McCarthy J J et al.. Aspirin resistance and a single gene.  Am J Cardiol. 2005;  95 805-808
• 65 Gum P A, Kottke-Marchant K, Welsh P A, White J, Topol E J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.  J Am Coll Cardiol. 2003;  41 961-965
• 66 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
• 67 Ziegler B K, Kristensen S D, Vissinger H, Jensen H K, Nielsen H K, Husted S E. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial.  Thromb Res. 2001;  104 175-180
• 68 Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis.  Am Heart J. 2005;  149 675-680
• 69 Zimmermann N, Wenk A, Kim U et al.. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.  Circulation. 2003;  108 542-547
• 70 Zimmermann N, Kurt M, Wenk A, Winter J, Gams E, Hohlfeld T. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?.  Eur J Cardiothorac Surg. 2005;  27 606-610
• 71 Vane J R, Botting R M. The mechanism of action of aspirin.  Thromb Res. 2003;  110 255-258
• 72 Ferraris V A, Ferraris S P. Limiting excessive postoperative blood transfusion after cardiac procedures. A review.  Tex Heart Inst J. 1995;  22 216-230
• 73 Weiss E J, Bray P F, Tayback M et al.. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.  N Engl J Med. 1996;  334 1090-1094
• 74 Di Castelnuovo A, de Gaetano G, Benedetta Donati M, Iacoviello L. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice.  Am J Pharmacogenomics. 2005;  5 93-99
• 75 Klinkhardt U, Dragutinovic I, Harder S. P-selectin (CD62p) and P-selectin glycoprotein ligand-1 (PSGL-1) polymorphisms: minor phenotypic differences in the formation of platelet-leukocyte aggregates and response to clopidogrel.  Int J Clin Pharmacol Ther. 2005;  43 255-263
• 76 Smith S M, Judge H M, Peters G et al.. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.  Platelets. 2005;  16 340-345
• 77 Angiolillo D J, Fernandez-Ortiz A, Bernardo E et al.. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.  Am J Cardiol. 2005;  96 1095-1099
• 78 Cambria-Kiely J A, Gandhi P J. Aspirin resistance and genetic polymorphisms.  J Thromb Thrombolysis. 2002;  14 51-58
• 79 Rozalski M, Boncler M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors.  Pharmacol Rep. 2005;  57 1-13
• 80 Ferraris V A, Ferraris S P, Camp P, Settles J, Fisher R. Gene expression abnormalities in aspirin hyper-responders.  J Thromb Haemost. 2005;  3 1525 (Abstract)
• 81 Weber C, Erl W, Pietsch A, Weber P C. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells.  Circulation. 1995;  91 1914-1917
• 82 Wu K K. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.  Semin Vasc Med. 2003;  3 107-112
• 83 Buchanan M R, Brister S J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.  Can J Cardiol. 1995;  11 221-227
• 84 Beving H, Eksborg S, Malmgren R S, Nordlander R, Rydén L, Olsson P. Inter-individual variations of the effect of low dose aspirin regime on platelet cyclooxygenase activity.  Thromb Res. 1994;  74 39-51
• 85 Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease.  Thromb Res. 2003;  110 281-286
• 86 Martin C P, Talbert R L. Aspirin resistance: an evaluation of current evidence and measurement methods.  Pharmacotherapy. 2005;  25 942-953
• 87 Lau W C, Gurbel P A, Watkins P B et al.. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.  Circulation. 2004;  109 166-171
• 88 Scott W J, Rode R, Castlemain B et al.. Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations.  J Thorac Cardiovasc Surg. 1992;  103 1001-1006 discussion 1006-1007
• 89 Monk T G, Goodnough L T. Blood conservation strategies to minimize allogeneic blood use in urologic surgery.  Am J Surg. 1995;  170 (6A, Suppl) 69S-73S
• 90 Scott W J, Kessler R, Wernly J A. Blood conservation in cardiac surgery.  Ann Thorac Surg. 1990;  50 843-851
• 91 Goodnough L T, Soegiarso R W, Geha A S. Blood lost and blood transfused in coronary artery bypass graft operation as implications for blood transfusion and blood conservation strategies.  Surg Gynecol Obstet. 1993;  177 345-351
• 92 Helm R E, Rosengart T K, Gomez M et al.. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion.  Ann Thorac Surg. 1998;  65 125-136
• 93 Weiskopf RBVM, Viele M K, Feiner J et al.. Human cardiovascular and metabolic response to acute, severe isovolemic anemia.  JAMA. 1998;  279 217-221
• 94 Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions.  Lancet. 1982;  2 1013-1015
• 95 Boneu B, Fernandez F. The role of the hematocrit in bleeding.  Transfus Med Rev. 1987;  1 182-185
• 96 Goodnough L T, Despotis G J. Transfusion medicine : support of patients undergoing cardiac surgery.  Am J Cardiovasc Drugs. 2001;  1 337-351
• 97 Carson JLNH, Noveck H, Berlin J A, Gould S A. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion.  Transfusion. 2002;  42 812-818
• 98 Carson JLDA, Duff A, Poses R M et al.. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity.  Lancet. 1996;  348 1055-1060
• 99 Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy.  Anesthesiology. 1996;  84 732-747
• 100 Royal College of Nursing and the Royal College of Surgeons of England . The administration of blood and blood components and the management of transfused patients. British Committee for Standards in Haematology, Blood Transfusion Task Force.  Transfus Med. 1999;  9 227-238
• 101 Utley J R. Pathophysiology of cardiopulmonary bypass: current issues.  J Card Surg. 1990;  5 177-189
• 102 Weisel R D, Charlesworth D C, Mickleborough L L et al.. Limitations of blood conservation.  J Thorac Cardiovasc Surg. 1984;  88 26-38
• 103 Cosgrove D M, Loop F D, Lytle B W et al.. Determinants of blood utilization during myocardial revascularization.  Ann Thorac Surg. 1985;  40 380-384
• 104 van Woerkens E C, Trouwborst A, van Lanschot J J. Profound hemodilution: what is the critical level of hemodilution at which oxygen delivery-dependent oxygen consumption starts in an anesthetized human?.  Anesth Analg. 1992;  75 818-821
• 105 Doak G J, Hall R I. Does hemoglobin concentration affect perioperative myocardial lactate flux in patients undergoing coronary artery bypass surgery?.  Anesth Analg. 1995;  80 910-916
• 106 Spahn D R, Smith L R, Veronee C D et al.. Acute isovolemic hemodilution and blood transfusion. Effects on regional function and metabolism in myocardium with compromised coronary blood flow.  J Thorac Cardiovasc Surg. 1993;  105 694-704
• 107 Zimmerman J L. Use of blood products in sepsis: an evidence-based review.  Crit Care Med. 2004;  32 (11 Suppl) S542-S547
• 108 Hardy J F. Current status of transfusion triggers for red blood cell concentrates.  Transfus Apheresis Sci. 2004;  31 55-66
• 109 Goodnough L T, Despotis G J, Hogue Jr C W, Ferguson Jr T B. On the need for improved transfusion indicators in cardiac surgery.  Ann Thorac Surg. 1995;  60 473-480
• 110 Fullerton D A, Campbell D N, Whitman G J. Use of human recombinant erythropoietin to correct severe preoperative anemia.  Ann Thorac Surg. 1991;  51 825-826
• 111 Monk T G. Preoperative recombinant human erythropoietin in anemic surgical patients.  Crit Care. 2004;  8 (Suppl 2) S45-S48
• 112 Fisher J W. Pharmacologic modulation of erythropoietin production.  Annu Rev Pharmacol Toxicol. 1988;  28 101-122
• 113 Means Jr R T. Clinical application of recombinant erythropoietin in the anemia of chronic disease.  Hematol Oncol Clin North Am. 1994;  8 933-944
• 114 Royston D, Bidstrup B P, Taylor K M, Sapsford R N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery.  Lancet. 1987;  2 1289-1291
• 115 Fergusson D A, Hébert P C, Mazer C D BART Investigators et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.  N Engl J Med. 2008;  358 2319-2331
• 116 Mangano D T, Tudor I C, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group . The risk associated with aprotinin in cardiac surgery.  N Engl J Med. 2006;  354 353-365
• 117 Mangano D T, Miao Y, Vuylsteke A Investigators of The Multicenter Study of Perioperative Ischemia Research Group et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.  JAMA. 2007;  297 471-479
• 118 Brown J R, Birkmeyer N J, O'Connor G T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.  Circulation. 2007;  115 2801-2813
• 119 Czerny M, Baumer H, Kilo J et al.. Complete revascularization in coronary artery bypass grafting with and without cardiopulmonary bypass.  Ann Thorac Surg. 2001;  71 165-169
• 120 Jones R H. Intraoperative crossover: the well-kept surgical secret to apparent surgical success.  J Am Coll Cardiol. 2005;  45 1529-1531
• 121 Liddicoat J E, Bekassy S M, Beall Jr A C, Glaeser D H, DeBakey M E. Membrane vs bubble oxygenator: clinical comparison.  Ann Surg. 1975;  181 747-753
• 122 Clark R E, Beauchamp R A, Magrath R A, Brooks J D, Ferguson T B, Weldon C S. Comparison of bubble and membrane oxygenators in short and long perfusions.  J Thorac Cardiovasc Surg. 1979;  78 655-666
• 123 Hicks G L, Zwart H H, DeWall R A. Membrane vs bubble oxygenators: a prospective study of 52 patients.  Arch Surg. 1979;  114 1285-1287
• 124 Hessel II E A, Johnson D D, Ivey T D, Miller Jr D W. Membrane versus bubble oxygenator for cardiac operations. A prospective randomized study.  J Thorac Cardiovasc Surg. 1980;  80 111-122
• 125 Sade R M, Bartles D M, Dearing J P, Campbell L J, Loadholt C B. A prospective randomized study of membrane versus bubble oxygenators in children.  Ann Thorac Surg. 1980;  29 502-511
• 126 Huber R, Mennicke C, Heitmann K U, Helling H J, Huber P M. Membrane versus bubble oxygenator in hyperthermic regional perfusion: a prospective randomized clinical study.  Eur Surg Res. 1994;  26 210-220
• 127 Tabak C, Eugene J, Stemmer E A. Erythrocyte survival following extracorporeal circulation. A question of membrane versus bubble oxygenator.  J Thorac Cardiovasc Surg. 1981;  81 30-33
• 128 Subramanian V A, Berger R L. Comparative evaluation of a new disposable rotating membrane oxygenator with bubble oxygenator.  Ann Thorac Surg. 1976;  21 48-54
• 129 Kleiman N S. A risk-benefit assessment of abciximab in angioplasty.  Drug Saf. 1999;  20 43-57